According to population-based studies, lung cancer is the prominent reason for cancer-
related mortality worldwide in males and is also rising in females at an alarming rate …

Although inhibition of cyclooxygenase-2 (COX-2) or the vascular endothelial growth factor
receptor (VEGFR) has been shown to be a promising antitumor strategy in non-small cell …

Background Lung cancer is a leading cause of cancer-related mortality worldwide, and
effective therapies are limited. Lung cancer is a leading cause of cancer-related mortality …

Sorafenib is an inhibitor of a number of intracellular signaling kinases with antiproliferative,
anti‑angiogenic and pro‑apoptotic effects in tumor cells. Sorafenib has been used in the …

Background/Aim: Sorafenib, an oral multi-kinase inhibitor, has been shown to improve the
outcome of patients with osteosarcoma (OS). However, the anti-OS effect and mechanism of …

Sorafenib is an anti-tumor drug widely used in clinical treatment, which can inhibit tyrosine
kinase receptor on cell surface and serine/threonine kinase in downstream Ras/MAPK …

Purpose: To investigate the role of macrophages in tumor progression under sorafenib
treatment and to explore whether combination of drugs that deplete macrophages improved …

Sorafenib (Sor) is clinical standard therapy for advanced hepatocellular carcinoma (HCC).
However, detailed molecular mechanism behind Sor-exerted pharmacological effect …

Background The treatment of non-small cell lung cancer (NSCLC) is challenging due to
immune tolerance and evasion. Salidroside (SAL) is an extract in traditional Chinese …

Approximately 85% of lung cancers are non–small-cell lung cancers (NSCLCs), which are
often diagnosed at an advanced stage and associated with poor prognosis. Currently, there …